Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC) Meeting Abstract
| Authors: | Harding, J. J.; Yarmohammadi, H.; Reiss, K. A.; Chou, J. F.; Capanu, M.; Do, R. K. G.; Khalil, D.; El Dika, I. H.; Ferrer, C. S.; Heffernan, O.; Giardina, J. D.; Merghoub, T.; Jarnagin, W. R.; Nadolski, G.; Erinjeri, J. P.; Soulen, M. C.; Tan, B. R.; Abou-Alfa, G. K. |
| Abstract Title: | Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC) |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900423 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.437 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 437 -- Meeting was conducted online as well as in person -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
